“
TL;DR
The study detected a statistically significant dose-response signal for reducing 24-hour cough count, with the 75 mg dose showing the largest reduction compared to placebo.
Lung · 13 authors, 12 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The study detected a statistically significant dose-response signal for reducing 24-hour cough count, with the 75 mg dose showing the largest reduction compared to placebo.
Participants were randomized 1:1:1:1 to receive twice-daily eliapixant 25 mg, 75 mg, 150 mg, or placebo for 12 weeks. The primary endpoint was the change from baseline in 24-hour cough count at 12 weeks. The study found a statistically significant dose-response signal for the primary endpoint. The largest relative and placebo-adjusted reductions in 24-hour cough count were seen in the 75 mg group. For example, the 75 mg group showed a 27% greater reduction versus placebo. Adverse events were common, with dysgeusia being the most frequent, occurring in a dose-related manner. One case of moderate drug-induced liver injury was reported in the 150 mg group. The study concluded that eliapixant demonstrated efficacy and a favorable taste tolerability profile in refractory chronic cough, but a liver injury led to intensified monitoring and discontinuation of the development program.